These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31912620)

  • 1. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
    Müller ML; Butler J; Heidecker B
    Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis.
    Plumadore E; Lombardo L; Cabral KP
    Am J Health Syst Pharm; 2022 Jan; 79(2):52-62. PubMed ID: 34491302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid.
    Hough A; Wearden J; de Almeida K; Kaiser S
    Curr Cardiol Rep; 2020 Aug; 22(10):106. PubMed ID: 32770401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
    Campbell CM; Baiyee CAMT; Almaani S; Bumma N; Sharma N; LoRusso S; Redder E; Bittengle J; Pfund K; Friemer M; Tong M; Kahwash R; Efebera Y; Parikh S; Vallakati A
    Am J Ther; 2023 Sep-Oct 01; 30(5):e447-e453. PubMed ID: 37713689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA; Mauermann ML; Grogan M; Coelho T
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
    Zibert A; Hüsing-Kabar A; Schmidt H
    Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
    Nuvolone M; Girelli M; Merlini G
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
    Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving landscape in the management of transthyretin amyloidosis.
    Hawkins PN; Ando Y; Dispenzeri A; Gonzalez-Duarte A; Adams D; Suhr OB
    Ann Med; 2015; 47(8):625-38. PubMed ID: 26611723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD; Dasgupta NR; Monia BP
    Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM; Zhang K; Lenihan DJ; Witteles R
    Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.